Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms
Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5′ and/or 3′ end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.
1 .- 127 . (canceled)
128 . A kit comprising:
a first dosage form comprising a JAK inhibitor; and
a second dosage form comprising a telomerase inhibitor.
129 . The kit according to claim 128 , wherein the JAK inhibitor is ruxolitinib or a pharmaceutically acceptable salt thereof.
130 . The kit according to claim 128 , wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.
131 . The kit according to claim 130 , wherein the telomerase inhibitor is imetelstat sodium.
132 . The kit according to claim 128 , wherein the first dosage form and the second dosage form are administered sequentially.
133 . The kit according to claim 132 , wherein the second dosage form is administered after the first dosage form.
134 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg/day to about 600 mg/day of the JAK inhibitor.
135 . The kit according to claim 128 , wherein the first dosage form comprises about 10 mg/day to about 400 mg/day of the JAK inhibitor.
136 . The kit according to claim 128 , wherein the first dosage form comprises about 10 mg/day to about 100 mg/day of the JAK inhibitor.
137 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg to about 40 mg the JAK inhibitor.
138 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg to about 25 mg the JAK inhibitor.
139 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg to about 20 mg the JAK inhibitor.
140 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg to about 15 mg the JAK inhibitor.
141 . The kit according to claim 128 , wherein the first dosage form comprises about 5 mg to about 10 mg the JAK inhibitor.
142 . The kit according to claim 128 , wherein the second dosage form comprises about 4 mg/kg to 10 mg/kg of the telomerase inhibitor.
143 . The kit according to claim 130 , wherein the second dosage form comprises about 8.9 mg/kg of imetelstat.
144 . The kit according to claim 131 , wherein the second dosage form comprises about 9.4 mg/kg of imetelstat sodium.
145 . The kit according to claim 128 , wherein the first dosage form is administered twice per day.
146 . The kit according to claim 128 , wherein the second dosage form is administered by intravenous infusion.
147 . The kit according to claim 128 , wherein the second dosage form is administered once every 4 weeks.